Rhizen Pharmaceuticals S.A. Announces Publication of Clinical Data from the Phase I/Ib study of Tenalisib (RP6530) in Patients with Relapsed/Refractory T-Cell Lymphoma (TCL)
September 24, 2020 14:00 ET
|
Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland, Sept. 24, 2020 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A. today announced the publication of the results from the Phase I/Ib study of Tenalisib (RP6530), the...
Rhizen Pharmaceuticals S.A. announces a scientific presentation on the therapeutic potential of their lead dual PI3K delta/gamma inhibitor in T-cell Lymphomas at the 18th Congress of European Hematology Association, 13-16 June 2013
June 12, 2013 05:08 ET
|
Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland, June 12, 2013 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A. announces a scientific poster
presentation on the therapeutic potential of its novel,...